JPH06199900A - Production of mucin - Google Patents

Production of mucin

Info

Publication number
JPH06199900A
JPH06199900A JP1587593A JP1587593A JPH06199900A JP H06199900 A JPH06199900 A JP H06199900A JP 1587593 A JP1587593 A JP 1587593A JP 1587593 A JP1587593 A JP 1587593A JP H06199900 A JPH06199900 A JP H06199900A
Authority
JP
Japan
Prior art keywords
mucin
saliva
ultrafiltration
bovine
submandibular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1587593A
Other languages
Japanese (ja)
Inventor
Yoshio Furusawa
良雄 古澤
Kenji Tamaki
健二 玉木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aska Pharmaceutical Co Ltd
Original Assignee
Teikoku Hormone Manufacturing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Hormone Manufacturing Co Ltd filed Critical Teikoku Hormone Manufacturing Co Ltd
Priority to JP1587593A priority Critical patent/JPH06199900A/en
Publication of JPH06199900A publication Critical patent/JPH06199900A/en
Pending legal-status Critical Current

Links

Landscapes

  • Peptides Or Proteins (AREA)

Abstract

PURPOSE:To readily obtain a high-purity mucin containing not fats by using saliva directly collected from bovine suborbital gland as a raw material. CONSTITUTION:A mucin is produced by separating the mucin from saliva of bovine suborbital gland. For example, bovine saliva is treated by cetavlon method to give a crude mucin hardly containing lipid, etc. The prepared crude mucin is further purified by ultrafiltration to give a high-purity mucin from which mucin fragments having <=100,000 molecular weight are removed. According to a preferable condition, a more purified mucin can be obtained by precisely filtering the crude mucin before the ultrafiltration.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、ウシ顎下腺から直接採
取した唾液を原料としてムチンを分離する、高純度で、
脂肪を含まないムチンの製法に関する。
TECHNICAL FIELD The present invention separates mucin from saliva directly collected from bovine submandibular gland as a raw material with high purity,
It relates to a method for producing fat-free mucin.

【0002】[0002]

【従来の技術】唾液腺ムチンは、哺乳動物、例えば、ウ
シ、ウマ、ブタ、ヒツジ等の唾液腺、すなわち顎下腺、
耳下腺および舌下腺等で生合成、分泌される糖蛋白質で
あって、動物の種類によって固有の粘稠性をもち、シア
ル酸を大量に含む分子量約10万〜100万の巨大分子
である。
BACKGROUND OF THE INVENTION Salivary gland mucin is a salivary gland of mammals such as bovine, equine, porcine and ovine, namely, submandibular gland,
It is a glycoprotein that is biosynthesized and secreted in the parotid gland and sublingual gland, and has a unique consistency depending on the type of animal. It is a macromolecule containing a large amount of sialic acid and having a molecular weight of about 100,000 to 1,000,000. is there.

【0003】ムチンは、優れた保湿作用及び乳化作用を
有し、また、人体に対する安全性も高いことが知られて
いる。近年、これらのムチンの特性に着目し、化粧品、
医薬品等(特に皮膚外用剤)の保湿剤として、また食
品、化粧品、医薬品、医薬部外品、トイレタリー等の各
種産業分野において、乳化剤としての利用の研究が進め
られている。
It is known that mucin has an excellent moisturizing action and emulsifying action and is highly safe for the human body. In recent years, focusing on the characteristics of these mucins, cosmetics,
Research is being conducted on its use as a moisturizer for pharmaceuticals (especially external skin preparations) and as an emulsifier in various industrial fields such as foods, cosmetics, pharmaceuticals, quasi-drugs, toiletries and the like.

【0004】唾液腺ムチンの分離・精製方法について
は、主としてウシ、ヒツジおよびブタの顎下腺を材料と
して現在まで詳細な検討が行われており、一般的に以下
の方法が広く用いられてきた。
The method for separating and purifying salivary mucins has been studied in detail up to the present, mainly using bovine, ovine and porcine submandibular glands, and the following methods have been widely used.

【0005】脂肪や結合組織を除去した顎下腺をホモジ
ナイズした後、適当な溶媒(水、0.1M NaCl、
0.05Mリン酸緩衝液(pH7.0)など)を2〜3
倍量加えて中性に保ちながら、5〜10時間攪拌、抽出
する。抽出液を数層のガーゼを通して不溶物を除き、濾
液を10,000×g、20分遠心すると透明な液が得
られる。ガーゼ上の残渣を同様に数回抽出に付し、全抽
出液を混合し精製する。精製は、前記抽出液を酸性(p
H3〜2.5)に調整するとムチンが他の蛋白質と結合
沈澱する性質を利用するムチンクロット法、硫安分画に
よる方法、Ba2+やCa2+の存在下でのアルコール分別
による方法、セタブロン(セチルトリメチルアンモニウ
ムブロマイド)や塩化セチルピリジニウム(CPC)な
どの四級アミンの陽性界面活性剤を使用する沈澱法など
により行われ、最終的には、透析等の手段が採られてい
た。
After homogenizing the submandibular gland from which fat and connective tissue have been removed, an appropriate solvent (water, 0.1M NaCl,
0.05M phosphate buffer (pH 7.0, etc.) 2-3
The mixture is added in an amount twice and the mixture is stirred and extracted for 5 to 10 hours while keeping the mixture neutral. The insoluble matter was removed from the extract through several layers of gauze, and the filtrate was centrifuged at 10,000 xg for 20 minutes to obtain a transparent solution. The residue on gauze is similarly extracted several times, and the whole extract is mixed and purified. For purification, the extract is acidified (p
H3 to 2.5), the mucin clot method, which utilizes the property that mucin binds and precipitates with other proteins, ammonium sulfate fractionation method, alcohol fractionation method in the presence of Ba 2+ and Ca 2+ , setablon (Cetyltrimethylammonium bromide), cetylpyridinium chloride (CPC), or other such precipitation method using a quaternary amine positive surfactant, and finally a means such as dialysis was adopted.

【0006】現在、上記精製方法のうち、セタブロンや
CPCを用いる沈澱法(以下、セタブロン法と呼ぶ)が
最も有効と認められている。
Of the above-mentioned purification methods, the precipitation method using setablon or CPC (hereinafter referred to as the setablon method) is currently considered to be the most effective.

【0007】セタブロン法によれば、顎下腺の抽出液に
セタブロンの5〜10%溶液を滴下すると、シアル酸を
含むムチンは、セタブロンとの複合体を形成し沈澱す
る。沈澱を高濃度の中性塩、たとえば、50%(w/
v)のCaCl2溶液に溶解し、アルコール分別を行う
と、50〜60%の濃度でムチンは沈澱する。沈澱した
ムチンを遠心して集めて透析後乾燥し、ムチン脱水末を
得る。
According to the setablon method, when a 5-10% solution of setablon is dropped into the submandibular gland extract, mucin containing sialic acid forms a complex with setablon and precipitates. The precipitate is concentrated to a high concentration of neutral salt, for example 50% (w /
When it is dissolved in the CaCl 2 solution of v) and alcohol fractionation is performed, mucin is precipitated at a concentration of 50-60%. The precipitated mucin is collected by centrifugation, dialyzed and dried to obtain a mucin dehydrated powder.

【0008】ムチンの収量は、顎下腺の生重量の0.2
〜0.5%であり、得られたムチンは電気泳動や超遠心
法では単一の成分であった。
The yield of mucin is 0.2 of the fresh weight of the submandibular gland.
.About.0.5%, and the obtained mucin was a single component by electrophoresis or ultracentrifugation.

【0009】[0009]

【発明が解決しようとする課題】しかしながら、上記の
従来方法では顎下腺組織の中に入り込んでいる脂肪も一
緒に抽出され、それを充分に取り除くのはなかなか困難
であるため、高純度で、脂肪を含まないムチンを容易に
得ることはできなかった。
However, according to the above-mentioned conventional method, fat invading the submandibular gland tissue is also extracted, and it is difficult to sufficiently remove it. Mucin without fat could not be easily obtained.

【0010】本発明は、ウシ顎下腺の導管へカニューレ
を挿入し、唾液を直接採取し、その顎下腺唾液を用いて
高純度で、脂肪を含まないムチンを得る方法を提供する
ことを目的としている。
[0010] The present invention provides a method for obtaining a high-purity, fat-free mucin using the submandibular saliva by inserting a cannula into a bovine submandibular canal and directly collecting saliva. Has an aim.

【0011】[0011]

【課題を解決するための手段】本発明者らは、上記目的
を達成するため、鋭意研究を重ねた結果、以下のように
すれば容易にウシの顎下腺唾液を採取できることを見い
だした。そして、ムチン製造の原料として従来全く知ら
れていなかったこの顎下腺唾液を用いれば、高純度で、
脂肪を含まないムチンが容易に得られることを見いだし
た。
Means for Solving the Problems As a result of intensive studies to achieve the above object, the present inventors have found that bovine submandibular saliva can be easily collected as follows. And if you use this submandibular saliva that has never been known as a raw material for mucin production,
We have found that mucin without fat can be easily obtained.

【0012】すなわち、ウシの顎下の皮膚を切開し、口
腔表皮近くで顎下腺導管を露出させ、わずか切開する。
そこへ皮膚の切開部からカニューレを導き、この導管の
開口部より顎下腺側に向けて差込む。一方、皮膚の切開
部傷口はカニューレを接着テープで固定しながら塞ぐ。
カニューレの先は適当な長さに延ばし、その先に受器を
置き、自然に流れ落ちる顎下腺唾液を採取する。採取さ
れた唾液は防腐剤を添加し、冷所に保管する。ここで、
防腐剤としては通常の防腐剤、例えば安息香酸類、パラ
オキシ安息香酸類、デヒドロ酢酸類、ソルビン酸類、フ
ェノール類、アルコール類、ハロゲン類、グルタールア
ルデヒド類、β−プロピオラクトン類などを、あるいは
これらを任意に組み合わせて用いることができるが、好
ましくは無臭のものか又は臭いがあっても後工程で容易
に除けるものが望ましく、特に、パラオキシ安息香酸類
が好適である。
That is, the submandibular skin of bovine is incised, the submandibular duct is exposed near the epidermis of the oral cavity, and a slight incision is made.
A cannula is introduced there through an incision in the skin, and is inserted toward the submandibular side from the opening of this conduit. On the other hand, the cut wound of the skin is closed while fixing the cannula with adhesive tape.
The tip of the cannula is extended to an appropriate length, a receiver is placed on the tip, and the submandibular saliva that spontaneously falls is collected. Add saliva to the collected saliva and store it in a cool place. here,
As the preservatives, usual preservatives, such as benzoic acids, paraoxybenzoic acids, dehydroacetic acids, sorbic acids, phenols, alcohols, halogens, glutaraldehydes, β-propiolactones, or the like, or Although they can be used in any combination, they are preferably odorless or those having an odor that can be easily removed in a subsequent step, and paraoxybenzoic acids are particularly preferable.

【0013】採取されたウシの唾液は、次いで、常法に
従いムチンの分離・精製処理に付される。分離・精製方
法としては、前記従来技術に記載した方法或いはそれ以
外の適用可能なあらゆる方法を用いることができ、例え
ば、ウシの唾液を前記セタブロン法により処理すること
により脂質等がほとんど含まれていない粗ムチンが得ら
れる。
The collected bovine saliva is then subjected to a mucin separation / purification treatment according to a conventional method. As the separation / purification method, any of the methods described in the above-mentioned prior art or any other applicable method can be used.For example, by treating bovine saliva with the setablon method, almost all lipids and the like are contained. No crude mucin is obtained.

【0014】得られた粗ムチンは、更に、限外濾過によ
り精製することにより、分子量10万以下のムチン断片
が除去された純度の高いムチンを得ることができる。従
来、ムチンのような高粘度で不溶物(繊維状のもの)を
含むものは限外濾過による精製には適さないと考えられ
ていたが、唾液腺ムチンの精製を限外濾過により行った
ところ、実用上濾過膜の目詰りの問題もなく、分子量1
0万以下のムチン断片や不純物が除去され、所望の分子
量10万以上のムチンが効率よく得られるのである。
The obtained crude mucin can be further purified by ultrafiltration to obtain highly pure mucin from which mucin fragments having a molecular weight of 100,000 or less have been removed. Conventionally, it was thought that those with high viscosity and insoluble matter (fibrous substance) such as mucin were not suitable for purification by ultrafiltration, but when purification of salivary gland mucin was performed by ultrafiltration, Practically, there is no problem of clogging of the filtration membrane, and the molecular weight is 1
Mucin fragments of less than 0,000 and impurities are removed, and the desired mucin having a molecular weight of 100,000 or more can be efficiently obtained.

【0015】ここで限外濾過とは、透析用半透膜やゲル
膜を用いる濾過によって懸濁物質を分散媒より分離する
操作を言う。透析用半透膜を用いる限外濾過法は、液体
に分散して存在する各種化合物が、膜の通過孔の大きさ
に応じて濾別されるものである。また、ゲル膜を用いる
限外濾過法では、膜に接した各種化合物の水溶液に圧力
をかけることにより、溶媒の水はゲル膜中に多量に保持
されている水分子と交換して拡散し、最終的には膜外に
流出する。この際、溶媒中に存在する低分子化合物も水
とともにゲル膜中に拡散し、濾過されて膜外に出るが、
粒子の大きい高分子化合物は、ゲル膜中での拡散速度が
低分子化合物に比べて非常に小さく、事実上ほとんど濾
過されず、結果として低分子化合物と高分子化合物の濾
別が行われる。また、ゲル膜には、平板状のものと、チ
ューブ状のものがある。限外濾過は蛋白質などの溶液を
非常に温和な条件で濃縮するのに適した方法である。
Here, ultrafiltration means an operation of separating a suspended substance from a dispersion medium by filtration using a dialysis semipermeable membrane or a gel membrane. The ultrafiltration method using a semipermeable membrane for dialysis is one in which various compounds existing in a dispersed state in a liquid are filtered out according to the size of the passage hole of the membrane. Further, in the ultrafiltration method using a gel membrane, by applying pressure to an aqueous solution of various compounds in contact with the membrane, the solvent water is diffused by exchanging with a large amount of water molecules retained in the gel membrane, Eventually it will flow out of the membrane. At this time, the low molecular weight compound existing in the solvent also diffuses into the gel film along with water and is filtered out of the film,
The polymer compound having large particles has a very low diffusion rate in the gel film as compared with the low molecular compound and is practically hardly filtered, and as a result, the low molecular compound and the polymer compound are filtered. In addition, the gel film is classified into a flat plate type and a tube type. Ultrafiltration is a method suitable for concentrating a solution such as protein under very mild conditions.

【0016】本発明で用いる限外濾過は、いわゆるゲル
膜を用いる限外濾過である。用いるゲル膜は分子量10
万前後で物質を分離することができるものであれば平板
状のものでも、チューブ状のものでもよい。本発明で用
いることができる平板状のゲル膜としては、YM100
(アミコン社製)等が挙げられる。チューブ状のゲル膜
としては、H1P100、H10P100,H10X1
00(以上アミコン社製)、SM14669(ザルトリ
ウス社製)、ペリコンPTHK(ミリポア社製)等が挙
げられる。
The ultrafiltration used in the present invention is a so-called gel filtration ultrafiltration. The gel film used has a molecular weight of 10
A flat plate-shaped one or a tube-shaped one may be used as long as the substances can be separated in about 10,000 times. The flat gel film that can be used in the present invention includes YM100
(Manufactured by Amicon) and the like. As the tubular gel film, H1P100, H10P100, H10X1
00 (above made by Amicon), SM14669 (made by Sartorius), Pellicon PTHK (made by Millipore) and the like.

【0017】加える圧力は通常0.5〜7kg/c
2、好ましくは1〜3kg/cm2の範囲である。流量
は、通常1〜10リットル/分、好ましくは2〜5リッ
トル/分である。
The applied pressure is usually 0.5 to 7 kg / c
m 2 , preferably in the range of 1 to 3 kg / cm 2 . The flow rate is usually 1 to 10 liters / minute, preferably 2 to 5 liters / minute.

【0018】濾過される粗ムチンの溶液の濃度は、通常
0.05〜1%であり、好ましくは0.1〜0.4%で
ある。
The concentration of the crude mucin solution to be filtered is usually 0.05 to 1%, preferably 0.1 to 0.4%.

【0019】本発明で使用しうる限外濾過装置として
は、アミコン社製ダイアフローホローファイバーシステ
ムDC30型、その他、ダウ社、ミリポア社、ザルトリ
ウス社、旭化成工業、バイオエンジニアリング社製のも
のが挙げられる。
Examples of the ultrafiltration device that can be used in the present invention include those manufactured by Amicon, Inc., Diaflow Hollow Fiber System DC30, and those manufactured by Dow, Millipore, Sartorius, Asahi Kasei and Bioengineering. .

【0020】本発明の好ましい態様によれば、粗ムチン
を限外濾過に付する前に精密濾過に付することにより、
より精製されたムチンを得ることができる。
According to a preferred embodiment of the present invention, the crude mucin is subjected to microfiltration prior to ultrafiltration,
More purified mucin can be obtained.

【0021】ここで精密濾過とは、懸濁物資を高精度に
捕捉する清澄濾過を意味し、具体的にはセルロース誘導
体やポリアミド、ナイロンなどの合成高分子を用いて微
細な0.2μmのオーダーのメッシュをもった多層膜
(メンブレンフィルター)を成形し、それを用いて溶媒
を清澄する操作をいう。なお、精密濾過を行う前には前
濾過と称し、セライトのような濾過助剤を用いた濾過、
あるいは粗いメッシュのフィルターを用いた濾過などの
処理で精密濾過膜の寿命を延ばすことは常套手段であ
る。
The term "microfiltration" as used herein means clarification filtration for trapping suspended matter with high precision, and specifically, it is made of synthetic polymer such as cellulose derivative, polyamide, nylon, etc. This is an operation of forming a multilayer film (membrane filter) having a mesh of, and using it to clarify the solvent. Before performing microfiltration, it is called prefiltration, and filtration using a filter aid such as Celite,
Alternatively, it is a common practice to extend the life of the microfiltration membrane by a treatment such as filtration using a coarse mesh filter.

【0022】精密濾過を行う場合、本発明で用いること
のできるフィルターの穴径は、通常0.2〜8.0μ
m、好ましくは0.45〜1.2μmである。従って、
本発明で使用しうるフィルターは、ウルチポアN66NN
XZP(ポール社製)、CWSC01TP3(ミリポア
社製)、SM5232406D1PH(ザルトリウス社
製)等である。精密濾過装置としては、ポール社、ミリ
ポア社、ザルトリウス社製のものが挙げられる。
When performing microfiltration, the pore size of the filter which can be used in the present invention is usually 0.2 to 8.0 μm.
m, preferably 0.45 to 1.2 μm. Therefore,
The filter that can be used in the present invention is Ultipore N 66 NN.
Examples include XZP (manufactured by Pall), CWSC01TP3 (manufactured by Millipore), SM5322406D1PH (manufactured by Sartorius), and the like. Examples of the microfiltration device include those manufactured by Pall, Millipore, and Sartorius.

【0023】精密濾過を行う場合、粗ムチンの濃度を
0.1〜0.4%(w/v)に希釈するのが好ましい。
限外濾過に先だって精密濾過を行うことにより、より効
率よく、分子量10万以上のムチンを精製・濃縮でき
る。
When performing microfiltration, it is preferable to dilute the concentration of crude mucin to 0.1 to 0.4% (w / v).
By performing microfiltration prior to ultrafiltration, mucin having a molecular weight of 100,000 or more can be purified and concentrated more efficiently.

【0024】尚、精密濾過を行わない場合には、チュー
ブ状のゲル膜を用いる限外濾過では、目づまりをおこす
ことがあるので、平板状のゲル膜を用いる方が好まし
い。以下、実施例により本発明を更に説明する。
If microfiltration is not performed, ultrafiltration using a tubular gel membrane may cause clogging, so it is preferable to use a flat gel membrane. Hereinafter, the present invention will be further described with reference to examples.

【0025】[0025]

【実施例】【Example】

実施例1 ウシの顎下腺唾液を採取し、防腐剤としてパラオキシ安
息香酸メチルを0.15%添加し、冷所に保存した。こ
の顎下腺唾液10リットルを冷却装置付き抽出機中で、
5〜10℃で攪拌しながら10%(w/v)CPC水溶
液を滴下して沈澱させた。滴下は沈澱が生じなくなるま
で続ける。この沈澱を集め、50%(w/v)塩化カル
シウム水溶液を加えて攪拌し、この液にエタノールを加
え、エタノール濃度60〜75%(v/v)の範囲で沈
澱するものを回収した。これに適当量のエタノールを加
えて脱CPC及び脱水し、エタノール沈澱物(粗ムチ
ン)を得た。
Example 1 Bovine submandibular saliva was collected, 0.15% of methyl paraoxybenzoate was added as a preservative, and the mixture was stored in a cool place. 10 liters of this submandibular gland saliva in an extractor with a cooling device,
A 10% (w / v) CPC aqueous solution was added dropwise with stirring at 5 to 10 ° C to cause precipitation. The dropping is continued until no precipitation occurs. The precipitates were collected, 50% (w / v) calcium chloride aqueous solution was added and stirred, and ethanol was added to this solution to recover precipitates in the ethanol concentration range of 60 to 75% (v / v). An appropriate amount of ethanol was added to this to remove CPC and dehydrate to obtain an ethanol precipitate (crude mucin).

【0026】実施例2 粗ムチン(顎下腺唾液10リットル相当量の)に水30
0ミリリットルを加えて溶解し、不溶物があるまま、透
析用チューブ(Visking透析チューブC−150
型、内径100mm)に詰め、水に対して透析した。透
析後、膜内液をとり、粗濾過で不溶物を除き、さらに精
密濾過装置(ポール社製、穴径1.2〜0.45μmフ
ィルター使用)を用いて細かい不溶物を除去した。この
ときムチン濃度はおよそ0.2%であった。次に、濾液
は11,000×g、20分間遠心分離して不溶物を除
き、凍結乾燥し、顎下腺ムチン10gを得た。このムチ
ンはシアル酸含量0.71%、蛋白質含量0.82%、
シアル酸/蛋白質比0.87であった。
Example 2 Crude mucin (corresponding to 10 liters of submandibular saliva) and water 30
Add 0 ml to dissolve, and insoluble matter remains (dialysis tube (Visking dialysis tube C-150)
The mold was filled in a mold having an inner diameter of 100 mm) and dialyzed against water. After dialysis, the in-membrane liquid was taken, insoluble matter was removed by rough filtration, and fine insoluble matter was removed using a precision filtration device (manufactured by Pall Co., using a filter having a hole diameter of 1.2 to 0.45 μm). At this time, the mucin concentration was about 0.2%. Next, the filtrate was centrifuged at 11,000 × g for 20 minutes to remove insoluble matter, and freeze-dried to obtain 10 g of submandibular gland mucin. This mucin has a sialic acid content of 0.71%, a protein content of 0.82%,
The sialic acid / protein ratio was 0.87.

【0027】実施例3 粗ムチン(顎下腺唾液10リットル相当量の)に水4リ
ットルを加えて溶解し、粗濾過で不溶物を除き、精密濾
過装置(ポール社製、穴径1.2〜0.45μmフィル
ター使用)を用いてさらに細かい不溶物を除去した。こ
のときムチン濃度はおよそ0.2%であった。次に、限
外濾過装置(アミコン社製ダイアフローホローファイバ
ーシステムDC4型、カートリッジHIP100−2使
用)を用いて分子量10万以下のものと塩類を排除し
た。限外濾過時の圧力は、0.7kg/cm2(10p
si)であり、流量は200ミリリットル/分であっ
た。濾液は11,000×g、20分間遠心分離して不
溶物を除き、凍結乾燥し、顎下腺ムチン8gを得た。こ
のムチンはシアル酸含量0.71%、蛋白質含量0.7
8%、シアル酸/蛋白質比0.91であった。
Example 3 4 liters of water was added to and dissolved in crude mucin (equivalent to 10 liters of submandibular saliva), insoluble matter was removed by coarse filtration, and a microfiltration device (manufactured by Pall Ltd., hole diameter 1.2) was used. .About.0.45 .mu.m filter was used) to remove finer insoluble matter. At this time, the mucin concentration was about 0.2%. Next, an ultrafiltration device (Diaflow Hollow Fiber System DC4 type manufactured by Amicon, using cartridge HIP100-2) was used to remove those having a molecular weight of 100,000 or less and salts. The pressure during ultrafiltration is 0.7 kg / cm 2 (10 p
si) and the flow rate was 200 ml / min. The filtrate was centrifuged at 11,000 × g for 20 minutes to remove insoluble matter and freeze-dried to obtain 8 g of submandibular mucin. This mucin has a sialic acid content of 0.71% and a protein content of 0.7.
The ratio was 8% and the sialic acid / protein ratio was 0.91.

【0028】[0028]

【発明の効果】ムチン製造の原料として従来全く知られ
ていなかった顎下腺唾液を用いることにより、高純度
で、脂肪を含まないムチンが容易に得られる。
EFFECT OF THE INVENTION By using submandibular saliva that has never been known as a raw material for producing mucin, mucin having high purity and containing no fat can be easily obtained.

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 ウシの顎下腺唾液からムチンを分離する
ことを特徴とするムチンの製法。
1. A method for producing mucin, comprising separating mucin from bovine submandibular saliva.
【請求項2】 分離したムチンを更に限外濾過により精
製する請求項1記載の方法。
2. The method according to claim 1, wherein the separated mucin is further purified by ultrafiltration.
【請求項3】 限外濾過の前に精密濾過を行う請求項2
記載の方法。
3. The microfiltration is performed before the ultrafiltration.
The described method.
JP1587593A 1993-01-06 1993-01-06 Production of mucin Pending JPH06199900A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP1587593A JPH06199900A (en) 1993-01-06 1993-01-06 Production of mucin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1587593A JPH06199900A (en) 1993-01-06 1993-01-06 Production of mucin

Publications (1)

Publication Number Publication Date
JPH06199900A true JPH06199900A (en) 1994-07-19

Family

ID=11900970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1587593A Pending JPH06199900A (en) 1993-01-06 1993-01-06 Production of mucin

Country Status (1)

Country Link
JP (1) JPH06199900A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829679B2 (en) 2005-08-12 2010-11-09 Riken Mucin-type glycoprotein and use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829679B2 (en) 2005-08-12 2010-11-09 Riken Mucin-type glycoprotein and use thereof

Similar Documents

Publication Publication Date Title
SU786854A3 (en) Method of producing protein serum-based preparate
DE2404041A1 (en) BLOOD FRACTIONATION PROCEDURE
DE3412144A1 (en) METHOD FOR PRODUCING HIGHLY CLEANED, ELECTRICITY-FREE, HEPATITIC-SAFE HUMAN AND ANIMAL HEMOGLOBIN SOLUTIONS
US4386068A (en) Antihemophilic factor concentrate and method for preparation
DE3587298T2 (en) Process for the purification of the hepatitis surface antigen and the product thus obtained.
DE2333883A1 (en) METHOD OF PRODUCING CLEANED ALBUMIN BY APPLICATION OF THERMOCOAGULATION AND THE OBTAINED CLEANED ALBUMIN
JPH07123927A (en) Method of recovering alpha-lactalbumin and beta - lactoglobulin from whey protein product
FR2584727A1 (en) PROCESS FOR EXTRACTING MILK PROTEINS, PRODUCTS, APPLICATION OF THE PROCESS, AND PHARMACEUTICAL COMPOSITIONS
US3429867A (en) Serum substantially free from gamma globulin and method of preparing same
Iwata et al. The organic matrix of urinary uric acid crystals
US4863609A (en) Process for the fractional separation of protein mixtures by means of membranes
EP0334776B1 (en) Cosmetical or pharmaceutical composition for cutaneous application, and process for the manufacture of such a composition
DE2636757A1 (en) METHOD OF CONCENTRATING AND PURIFYING THE ANTIHAEMOPHILIC FACTOR
JPS626693B2 (en)
EP1176979A1 (en) High concentration immunoglobulin preparation and method for its production
US3461205A (en) Process of extracting proteins from potatoes
JPH06199900A (en) Production of mucin
JPH05310799A (en) Method for purifying mucin
EP1624057B1 (en) Pharmaceutical composition containing hyaluronidase and uses thereof
US3472831A (en) Process for purifying mistletoe proteins by ultracentrifugation
DE2014957C2 (en) Process for purifying proteins from blood serum or plasma
JP2001072693A (en) Production of purified yolk lecithin
US4507205A (en) Process for the purification of glucosaminoglucans
JP2005336230A (en) Method of separation and recovery of lipid in membrane material of fat globule
US2687980A (en) Thromboplastin product and method for preparing same

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20031002